PCSK9 and atherosclerosis: Collectively, these studies, spanning both clinical application and mechanistic exploration, demonstrate the significant value of PCSK9 inhibitors in enhancing HDL functionality and attenuating the progression of atherosclerosis, thereby providing a robust theoretical and practical foundation for the prevention and treatment of cardiovascular diseases.